Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma (Q38401805)

2 September 2017

Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma (English)

1 reference

2 September 2017

1 reference

11

Anil K Sood

1 reference

2 September 2017

Jun Zhou

1

1 reference

2 September 2017

Ju-Won Roh

2

1 reference

2 September 2017

Sudeshna Bandyopadhyay

3

1 reference

2 September 2017

Zhengming Chen

4

1 reference

2 September 2017

Adnan R Munkarah

5

1 reference

2 September 2017

Yaser Hussein

6

1 reference

2 September 2017

Baraa Alosh

7

1 reference

2 September 2017

Tarek Jazaerly

8

1 reference

2 September 2017

Kinda Hayek

9

1 reference

2 September 2017

Assaad Semaan

10

1 reference

2 September 2017

Rouba Ali-Fehmi

12

1 reference

2 September 2017

language of work or name

English

0 references

publication date

4 August 2012

1 reference

2 September 2017

1 reference

2 September 2017

128

1 reference

2 September 2017

2

1 reference

2 September 2017

344-348

1 reference

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

2 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

Profiling of Endogenous Estrogens, Their Precursors, and Metabolites in Endometrial Cancer Patients: Association with Risk and Relationship to Clinical Characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

Molecular pathogenesis of endometrial and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

Normal endometrial stromal cells regulate survival and apoptosis signaling through PI3K/AKt/Survivin pathway in endometrial adenocarcinoma cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

Decreased carbonyl reductase 1 expression promotes malignant behaviours by induction of epithelial mesenchymal transition and its clinical significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

Aberrations of EZH2 in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

TNF inhibits Notch-1 in skeletal muscle cells by Ezh2 and DNA methylation mediated repression: implications in duchenne muscular dystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

Quantitative in vivo imaging of the effects of inhibiting integrin signaling via Src and FAK on cancer cell movement: effects on E-cadherin dynamics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

Current concepts in the pathology and epigenetics of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

Clinical/pathologic features and patient outcome in early onset endometrial carcinoma: a population based analysis and an institutional perspective from the Detroit metropolitan area, Michigan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

Factors associated with Type I and Type II endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

To match or not to match in epidemiological studies--same outcome but less power

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

Src kinases as therapeutic targets for cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.07.128

10.1016/J.YGYNO.2012.07.128

7 January 2021

Identifiers

DOI

1 reference

2 September 2017

1 reference